Oral estrogen replacement therapy versus placebo for hot flushes: A systematic review

Climacteric

Volumn 4, Issue 1, 2001, Pages 58-74

  MacLennan, A ^a   Lester, S ^a   Moore, V ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cochrane collaboration; Estrogen; Hot flushes; HRT; Menopause; Meta analysis; Vasomotor symptoms

Indexed keywords

ESTROGEN; PLACEBO; PROGESTERONE;

ARTHRALGIA; CLINICAL TRIAL; DISEASE SEVERITY; EDEMA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MASTALGIA; MENOPAUSE; MENTAL DISEASE; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; SWEATING; VASOMOTOR REFLEX;

EID: 0035026890     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.4.1.58.74     Document Type: Review

References (52)

1. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-8
2. Porter M, Penney GC, Russell D, Russell E, Templeton A. A population based survey of women's experience of the menopause. Br J Obstet Gynaecol 1996;103:1025-8
3. Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997;27:203-14
4. Sturdee D, Brincat M. The hot flush. In Studd JWW, Whitehead MI, eds. The Menopause. London: Blackwell Scientific, 1988:24-42
5. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109
6. MacLennan AH, Paine BJ, Marley JE. Australian women's likelihood of participation in WISDOM. Aust Fam Physician 2000;29:1-5
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
8. Baujat B, Mahe C, Guerin S, Pignon J-P. Detection of outlying and influential trials: a graphical method to explore heterogeneity in meta-analysis. Presented at the VII Cochrane Colloquium. The best evidence for health care: the role of the Cochrane Collaboration. Rome, October 1999
9. Thompson SG, Sharp S. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999;18:2693-708
10. Whitehead A, Bailey AJ, Elbourne D. Combining summaries of binary outcomes with continuous outcomes in a meta-analysis. J Biopharm Stat 1999;9:1-16
11. Whitehead A, Jones NM. A meta-analysis of clinical trials involving different classifications of response into ordered categories. Stat Med 1994;13:23-4
12. Blumel JE, Roncagliolo ME, Gramegna G, Vasquez R, Estartus AT. Estudio doble ciego del efecto sobre la sintomatologia menopausica, et perfil lipidico y el grosor endometrial de una terapia continua de valerato de estradiol mas acetato de medroxiprogesterona [Double blind method of the effect of menopause symptoms, lipid profile, and endometrial thickness of continuous therapy with estradiol valerate and medroxyprogesterone acetate]. Rev Chil Obstet Ginecol 1994;59;534-60
13. Chung TKH, Yip SK, Lam P, Chang AMZ, Haines CJ. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms. Maturitas 1996;25:115-23
14. Conard J, Basdevant A, Thomas J-L, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrel acetate and estradiol. Fertil Steril 1995;64:957-62
15. Archer DR, Fischer LA, Rich D, et al. Estrace vs. Premarin for treatment of menopausal symptoms: dosage comparison study. Adv Ther 1992;9:21-31
16. Baerug U, Winge T, Nordland G, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998;1:219-28
17. Baumgardner SB, Condrea H, Daane TA, et al. Replacement estrogen therapy for menopausal vasomotor flushes. Comparison of quinestrol and conjugated estrogens. Obstet Gynecol 1978;51:445-52
18. Bech P, Munk-Jensen N, Obel EB, Ulrich LG, Eiken P, Pors Nielsen S. Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures. Psychother Psychosom 1998;67:259-65
19. Obel EB, Munk-Jensen N, Svenstrup B, et al. A two-year double-blind controlled study of the clinical effects of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993;16:13-21
20. Campbell S. Double blind psychometric studies on the effects of natural estrogens on postmenopausal women. In Campbell S, ed. The Management of the Menopause and Post Menopausal Years. Lancaster: MTP, 1976:149-55
21. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977;4:31-46
22. Coope J, Thomson JM, Poller L. Effects of 'natural oestrogen' replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975;4:139-43
23. Coope J. Double blind cross-over study of estrogen replacement therapy. In Campbell S, ed. The Management of the Menopause and Post Menopausal Years. Lancaster: MTP, 1976:159-68
24. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981;31:134-40
25. Poller L, Coope J. A double-blind cross-over study of piperazine oestrone sulphate and placebo with coagulation studies. Br J Obstet Gynaecol 1980;87:718-25
26. Davidsen PCB, Secher HJ, Pedersen GT, Christennnsen N. Sekvensterapi med ostradiol-valerat/norgestrel i klimakteriet [Cyclical therapy with estradiol valerate/norgestrel at the menopause. Report of a double-blind investigation]. Ugeskr Laeg 1974;136:1805-8
27. Dennerstein L, Burrows GD, Hyman GJ, Sharpe K. Hormone therapy and affect. Maturitas 1979;1:247-59
28. Dennerstein LL, Burrows GD, Hyman G. Menopausal hot flushes: a double blind comparison of placebo, ethinyl oestradiol and noregestrel. Br J Obstet Gynaecol 1978;85:852-6
29. Dennerstein L, Fotherby K, Burrows GD, Senior J, Wood C. Hormone replacement therapy at the menopause. Double blind controlled study of women's preferences. NZ J Obstet Gynaecol 1978;18:139-43
30. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy - a placebo controlled study. Int J Fertil Menopausal Stud 1995;40:73-8
31. Hagen C, Christensen M, Christiansen C, Stocklund K-E, Transbol I. Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period. Acta Obstet Gynecol Scand 1982;3:237-41
32. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund K, Transbol IB. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9
33. Jensen J, Christiansen C. Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-controlled therapeutic trial. Maturitas 1985;5:125-33
34. Christensen M, Hagen C, Christiansen C, Transbol I. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873-9
35. Jensen PB, Jensen J, Riis BJ, Rodbro P, Strom V, Christiansen C. Climacteric symptoms after oral and percutaneous hormone replacement therapy. Maturitas 1987;9:207-15
36. Jensen J, Riis BJ, Christiansen C. Cyproterone acetate, an alternative progestogen in postmenopausal hormone replacement therapy? Effects on serum lipids and lipoproteins. Br J Obstet Gynaecol 1987;94:136-41
37. Christiansen C, Nilas L, Riis BJ, Rodbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985;2:800-1
38. Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms and bleeding. Obstet Gynecol 1992;79:202-9
39. Marslew U, Riis B, Christiansen C. Progestogens: therapeutic and adverse effects in early postmenopausal women. Maturitas 1991;13:7-16
40. Martin PL, Burnier AM, Segre EJ, Huix FJ. Graded sequential therapy in the menopause: a double-blind study. Am J Obstet Gynecol 1971;111:178-86
41. Paterson ME. A randomised, double-blind, cross-over study into the effect of sequential mestranol and norethisterone on climacteric symptoms and biochemical parameters. Maturitas 1982;4;83-94
42. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions trial. Obstet Gynecol 1998;92:982-8
43. Espeland MA, Bush TL, Mebane-Sims I, et al. for the PEPI trial investigators. Rationale, design and conduct of the PEPI trial. Control Clin Trials 1995;16(Suppl 4):3-19
44. Miller VT, Byington RL, Espeland MA, et al. Baseline characteristics of the PEPI participants. Postmenopausal Estrogen/Progestin Interventions. Control Clin Trials 1995;16(Suppl 4):54-65
45. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-208
46. Vikhlyaeva EM, Zaidieva YaZ, Lobova TA, Shishkina AV, Larsen S. Trisequens in perimenopausal women with climacteric syndrome: a randomised double-blind trial. Acta Obstet Gynecol Scand 1997;76:167S(abstr P86.19)
47. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001;1:in press
48. Nachtigall LE, Nachtigall LB. The effects of isoflavones derived from red clover on vasomotor symptoms and endometrial thickness. Proceedings of the Ninth International Menopausal Society World Congress on the Menopause. Climacteric 1992;2(Suppl 1):128
49. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. J Am Med Assoc 1996;17:1397-404
50. Helton ED, Goldzieher JW. Pharmacokinetics of ethinyl estrogens: a review. Contraception 1981;15:255-84
51. MacLennan AH, MacLennan A, Wenzel S, Chambers H, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993;159:102-6
52. Norman RJ, Flight, IHK, Rees MCP. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and postmenopausal women: weight and body fat distribution. The Cochrane Library Oxford: Update Software, 1999:1